The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine has updated the scheduled presentation time for its upcoming appearance at an investor conference.
The company directed stakeholders to its full press release for detailed information regarding the timing adjustment and any implications for interested parties. The revised schedule underscores the importance Editas Medicine places on clear communication with its investors within the biotech sector.
Earlier this year, Editas Medicine released first quarter 2026 results and a business update detailing progress in its gene editing programs. The company recently presented new preclinical data for its gene editing candidate EDIT-401 at EASCongress2026. These events reflect ongoing activity in Editas Medicine’s research and investor communications.